Secondary analysis
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
- Secondary analysis of the EMPEROR-Preserved randomised trial
Cox regression adjusted for demographic and clinical confounders; mixed model for repeated measures
Authors' conclusion
In HFpEF, the prevalence of resHTN is high and is associated with frequently higher outcome rates compared with ctrHTN and uctrHTN. The treatment effect was not modified by hypertension categories.
Study context
- Population
- Patients with heart failure with preserved ejection fraction (HFpEF) in the EMPEROR-Preserved trial
- Participants
- 5,533 patients
- Comparison
- Empagliflozin effects by hypertension category
- Primary endpoint
- Primary endpoint of EMPEROR-Preserved: treatment effect of empagliflozin by hypertension category
Primary result
As reported in the abstract
Primary endpoint by hypertension category
Primary endpoint more prevalent in resHTN
P = .0358
Treatment effect of empagliflozin on primary endpoint similar in resHTN, uctrHTN and ctrHTN
P for interaction = .92
Further findings
eGFR slope improvement by hypertension category
- Improvement similar across hypertension categories
- P for interaction = 0.95
Quality of life change by hypertension category
- Change similar across hypertension categories
Systolic blood pressure (SBP)
- Empagliflozin reduced SBP in resHTN slightly more than in other categories in the first weeks; thereafter no significant differences
- Modest SBP reduction: moderate increase in time at target and reduced hypertensive urgencies
Original publication
Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J. Published 4 March 2025. doi:10.1093/eurheartj/ehae938
Summarised from the published abstract; every number is checked against it